revenue $10.9M, net income -$44.9M. Nektar raises, advances rezpegaldesleukin to Phase 3 after positive atopic dermatitis data

Filed May 8, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~2 min read

Key Changes

• high

  Phase 2b REZOLVE-AD trial met primary endpoint with statistical significance across all dose arms (p<0.001), demonstrating efficacy in atopic dermatitis and supporting Phase 3 initiation.

  MD&A: Clinical Development verify on EDGAR →
• high

  Company raised $1.1 billion in equity from July 2025 to April 2026, increasing cash and investments from $220.7M to $731.6M and providing runway for Phase 3 program without near-term financing risk.

  MD&A: Liquidity verify on EDGAR →
• high

  FDA granted Fast Track designation for rezpegaldesleukin in severe alopecia areata in July 2025, potentially expediting regulatory review if clinical trials succeed.

  MD&A: Regulatory Milestones verify on EDGAR →